Irisin in patients with nonalcoholic fatty liver disease
Irisin in patients with nonalcoholic fatty liver disease
复制标题
DOI：
10.1016/j.metabol.2013.09.013
复制
发表时间：
2014-02-01
影响因子：
9.8
通讯作者：
Mantzoros, Christos S.
中科院分区：
文献类型：
--
作者：
Polyzos, Stergios A.;Kountouras, Jannis;Mantzoros, Christos S.
Objective. Irisin是最近发现的一种肌因子，被提出用于增加产热相关的能量消耗和改善新陈代谢。我们旨在比较评估活检证实的非酒精性脂肪性肝病（NAFLD）患者与对照组的血清鸢尾素水平，并研究其与疾病严重程度的相关性。分别招募了15例和16例经活检证实的非酒精性单纯性脂肪变性（NAFL）和脂肪性肝炎（NASH）患者，以及24例无NAFLD的瘦型和28例肥胖对照。测定鸢尾素、脂肪因子和生化指标。肥胖对照组的血清鸢尾素水平有统计学差异（33.7 +/- 2.7 ng/mL; p
Objective. Irisin is a recently discovered myokine proposed to increase thermogenesis-related energy expenditure and improve metabolism. We aimed to comparatively evaluate serum irisin levels in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) vs. controls and study their association with disease severity.Methods. Fifteen and 16 consecutively enrolled patients with biopsy-proven nonalcoholic simple steatosis (NAFL) and steatohepatitis (NASH), respectively, and 24 lean and 28 obese controls without NAFLD were recruited. Irisin, established adipokines and biochemical tests were measured.Results. Serum irisin levels were statistically different in obese controls (33.7 +/- 2.7 ng/mL; p